Hepatitis B
Coverage of the 2017 EASL International Liver Congress
- Details
- Category: Hepatitis B
- Published on Sunday, 30 April 2017 00:00
- Written by HIVandHepatitis.com
HIVandHepatitis.com coverage of the 2017 International Liver Congress, annual meeting of the European Society for the Study of the Liver, April 19-23, 2017, in Amsterdam.
Hepatitis C
- AbbVie Combination Cures Most People with Genotype 3 Hepatitis C
- New AbbVie Hepatitis C Combination Cures 99% of People with Cirrhosis
- Triple Combination Cures Most Hepatitis C Patients with Prior DAA Failure
- Children with Hepatitis C Respond Well to Sofosbuvir/Ledipasvir
- Generic Hepatitis C Drugs Continue to Produce High Cure Rates
- Albumin Reduces Complications of Decompensated Cirrhosis and Improves Survival
Hepatitis B and D
- Besifovir and Tenofovir Exalidex Look Promising for Hepatitis B
- EASL Releases Updated Hepatitis B Guidelines at International Liver Congress
- Switching to TAF for Hepatitis B Improves Kidney Function and Bone Loss
Complications and Comorbidities
- Hepatitis C Treatment Allows 1 in 4 to Come Off Liver Transplant Waiting List
- Direct-Acting Antivirals for Hepatitis C Not Linked to Higher Liver Cancer Risk
- Curing Hepatitis C Reduces Cardiovascular Risk
- Nivolumab Increases Survival for People with Advanced Liver Cancer
- Norfloxacin Reduces Risk of Death for People with Decompensated Cirrhosis